Innate and adaptive resistance mechanisms to arginine deprivation therapies in sarcoma and other cancers

Leonard C. Rogers¹, Brian A. Van Tine¹,²

¹Division of Medical Oncology, Washington University in St. Louis, St. Louis, MO 63110, USA.
²Alvin J Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO 63110, USA.

Correspondence to: Prof. Brian A. Van Tine, Division of Medical Oncology, Washington University in St. Louis, St. Louis, MO 63110, USA. E-mail: bvantine@wustl.edu

How to cite this article: Rogers LC, Van Tine BA. Innate and adaptive resistance mechanisms to arginine deprivation therapies in sarcoma and other cancers. Cancer Drug Resist 2019;2:516-26. http://dx.doi.org/10.20517/cdr.2019.49

Received: 14 Jun 2019  First Decision: 1 Aug 2019  Revised: 11 Aug 2019  Accepted: 13 Aug 2019  Published: 19 Sep 2019

Science Editor: Helen M. Coley  Copy Editor: Jia-Jia Meng  Production Editor: Tian Zhang

Abstract
Many cancers lack functional expression of the enzyme argininosuccinate synthetase 1 (ASS1) that is necessary for synthesis of L-arginine. These cancers must import arginine for survival and growth, and this reliance can be targeted by arginine-degrading extracellular enzymatic drugs, most commonly PEGylated arginine deiminase. These enzymes can become targets of the immune system, reducing their effectiveness, but PEGylation improves the in vivo stability. Arginine deprivation causes cell death in some cancers, but others gain resistance by expressing ASS1 after a starvation response is induced. Other resistance mechanisms are possible and explored, but these have not been observed specifically in response to arginine deprivation. Future studies, especially focusing on the mechanisms of ASS1 upregulation and metabolic adaptations, may yield insights into preventing or taking advantage of resistance adaptations to make arginine deprivation therapy more effective.

Keywords: PEGylated arginine deiminase, argininosuccinate synthetase 1, resistance, metabolism, arginine

INTRODUCTION
Our understanding of metabolic therapies and how to use them clinically is rapidly evolving. Current therapies based on tumor metabolism are focused on glutaminase inhibitors, isocitrate dehydrogenase inhibitors, pyruvate transport via monocarboxylate transporter 1, and amino acid-degrading enzymes that target asparagine or arginine. It is the ability to systematically degrade arginine and how to apply
this clinically that is the focus of this review. Currently, arginine starvation results in an adaptive metabolic reprogramming that renders cells resistant to arginine starvation [1-3]. By better understanding the mechanisms of this adaptation, successful therapeutic strategies based on arginine starvation and its related biomarker argininosuccinate synthetase 1 (ASS1) will result.

Amongst the more commonly arginine auxotrophic cancers are all the subtypes of sarcoma. Regardless of histology, about 88% lack significant expression of ASS1 [1]. This finding is not unique to sarcoma, as most solid tumors, including many melanomas, bladder cancers, prostate cancers, small cell lung cancers, and hepatocellular carcinomas, are deficient in this enzyme [4-9].

Sarcomas often originate in muscle and bone, and these two tissues, along with the heart and lungs, are among the lowest ASS1 mRNA-expressing tissues in the body [10-12]. The high incidence of ASS1 silencing in sarcoma may be a consequence of its tissues of origin, but this is a subject of ongoing research. This explanation is also supported by the fact that the ASS1 gene is rarely mutated or deleted in cancer. Rather, its transcription is regulated by epigenetic modifications and transcription factors [13-16]. A common mechanism of ASS1 silencing is hypermethylation of its promoter region, causing decreased transcription [13,14,16]. Some cancers have also shown competition between the repressive HIF-1α and activating c-Myc transcription factors binding to the E-box of the ASS1 promoter [16]. These are all reversible regulation mechanisms that can dynamically respond when the cell is stressed by a lack of arginine. Further work to fully understand the nature of ASS1 silencing in sarcomas is ongoing.

**UREA CYCLE**

The urea cycle in humans, shown in full in Figure 1, takes place mainly in the liver as a way to convert waste ammonia to urea. Ammonia is first converted to carbamoyl phosphate by condensation with
carbonic acid and a phosphate group, a reaction catalyzed by carbamoyl phosphate synthetase I[17]. The carbamoyl phosphate is then condensed with ornithine with the loss of inorganic phosphate, catalyzed by ornithine transcarbamoylase, forming citrulline[17]. ASS1 then catalyzes the condensation of aspartate with citrulline to form argininosuccinate[17]. Argininosuccinate lyase (ASL) then cleaves argininosuccinate into fumarate and arginine[17]. The arginine is subsequently hydrolyzed into ornithine and urea by arginase 1[17].

Although urea production is its main purpose, the cycle is not isolated and exchanges intermediates with other pathways in the cell. In fact, many cells outside the liver do not perform the full cycle but use portions for other functions, namely to produce nitric oxide (NO) and synthesize arginine, as shown in Figure 1. In adult humans, the kidneys import extracellular citrulline to synthesize arginine for the rest of the body[18]. Because of this, most cells in the body have no need to produce arginine, but many still employ part of the urea cycle to produce NO. This is achieved by the enzyme nitric oxide synthase (NOS), using arginine and oxygen to produce NO and citrulline[19]. The citrulline can then be recycled to arginine by ASS1 and ASL, in what is sometimes called the citrulline-NO cycle[19].

**FUNCTIONAL CONSEQUENCES OF ASS1 SILENCING**

There are many possible benefits of suppressing ASS1. The leading hypothesis is that silencing this gene may accelerate cellular growth by causing an increase in available aspartate[20]. Aspartate is consumed in the essentially irreversible reaction catalyzed by ASS1 to ligate citrulline and aspartate [Figure 1][17]. ASS1 deficiency therefore increases levels of aspartate, which is needed to make pyrimidines for nucleotide synthesis, allowing cell proliferation. In fact, the lethal metabolic disorder citrullinemia type I, caused by ASS1 deficiency or mutation, results in increased pyrimidine synthesis and proliferation[20]. Supporting this hypothesis are multiple studies that have shown aspartate to be a key limiting metabolite for the growth of cancer cells[21,22].

Another possibility is that ASS1 downregulation helps maintain a higher intracellular pH under acidic stress in the tumor microenvironment[23]. This happens when the urea cycle cannot function due to ASS1 loss, leaving basic ammonia free in the cells to scavenge protons. The net consequence of this is increased intracellular pH. Recently, another beneficial role has been proposed for ammonia in cancer, as its nitrogen may be directly incorporated into amino acids to maximize growth efficiency[24]. There are likely other beneficial reasons that are yet to be elucidated.

ASS1 deficiency is also predicted to decrease cellular levels of fumarate, a product of the urea cycle downstream of ASS1. Although this metabolite seems to be unexplored in the context of ASS1 deficiency, any decrease is unlikely to be beneficial, considering that excess fumarate has been found to induce epithelial-to-mesenchymal-transition and promote cancer progression[25]. ASS1 is also essential in the citrulline-NO cycle that produces NO for signaling[19]. However, the citrulline-NO cycle is not necessary, as the substrate needed for NO synthesis is arginine, which can normally be imported from extracellular sources. Regardless of the advantages conferred by ASS1 deficiency, this state renders the cells sensitive to arginine deprivation in a targetable way.

Multiple enzymes are capable of targeting ASS1-deficient cells by degrading arginine in the bloodstream. Arginine decarboxylase (ADC) can be found in bacteria, plants, and mammals[26]. ADC converts arginine to agmatine, which is toxic to normal cells and cannot be converted back to arginine, thus limiting the therapeutic potential of this enzyme[26]. NOS could also theoretically be used to degrade arginine in the blood, but the increased NO levels may have unintended signaling effects, and NOS has not been used in this fashion to our knowledge. Recombinant human arginase I has been adapted as a drug to degrade extracellular arginine[26]. The effectiveness has been greatly improved over time by several modifications, but arginase is less commonly used as a therapy than the following enzyme because of its lower affinity
for arginine\(^\text{[6,26]}\). The most widely used of the arginine-degrading enzymes is arginine deiminase, an enzyme found in many microbial organisms that hydrolyzes arginine into citrulline and ammonia\(^\text{[6,27]}\). Arginine deiminase has been conjugated to polyethylene glycol of 20 kDa average size (PEGylated arginine deiminase (ADI-PEG20)), helping to increase its \textit{in vivo} half-life drastically\(^\text{[28]}\).

This drug is being tested in multiple clinical trials and is very promising for multiple reasons. First, it deprives the entire body of arginine regardless of whether the site is accessible, as demonstrated by its efficacy against intracranial glioblastoma, which is protected by the blood brain barrier\(^\text{[29]}\). Importantly, ADI-PEG20 has strong effects on ASS1-deficient tumors while having only benign side effects of injection site rash and increased uric acid levels. These differing effects on normal tissues versus tumors can be at least partially explained by the fact that most cells in the body express ASS1. The liver and kidneys have extremely high levels of the enzyme, as the liver performs the urea cycle for the body, and the kidneys produce excess arginine to export to the blood\(^\text{[18]}\). Most other tissues express varying levels of ASS1 for less clear reasons, but it may be to carry out the citrulline-NO cycle\(^\text{[19]}\). Further explaining the more severe response to ADI-PEG20 in cancer specifically is the increased rate of growth in tumors. While heart, lung, muscle, and bone express very low levels of ASS1, these tissues are relatively static in their growth and therefore unaffected compared to rapidly proliferating cancer cells. When starved of arginine, ASS1-deficient cancers are forced into cytostasis and have been shown to rely partially on autophagy for survival\(^\text{[4]}\). Other methods of arginine acquisition likely also play a part and will be discussed later.

**RESISTANCE**

\textbf{Adaptive resistance}

Some ASS1-deficient cancers undergo cell death when starved of arginine by ADI-PEG20, but many others gain resistance to arginine deprivation\(^\text{[1-3]}\). This is especially common in sarcomas, as they usually do not die as a consequence of arginine starvation\(^\text{[1,2]}\). The most obvious pathway to resistance is upregulation of ASS1 expression. Indeed, this is the only cellular long-term resistance mechanism that has been confirmed to occur in response to ADI-PEG20\(^\text{[1,6,15,30]}\). This path is open to nearly every ASS1-deficient cancer, as mutation or deletion of ASS1 is rare compared to transcriptional silencing. Virtually all regulation of ASS1 has been found at the transcriptional level, and the mechanisms by which ASS1 is upregulated in response to arginine deprivation are the subject of much research.

\textbf{Figure 2} illustrates the fully repressed and fully active states of the ASS1 promoter and shows how arginine deprivation can lead to increased ASS1 expression and resistance to ADI-PEG20. In ASS1-deficient lymphoid malignancies, demethylation of the ASS1 promoter with a demethylating agent has been shown to rescue cells from ADI-PEG20 treatment\(^\text{[13]}\). More importantly, ASS1-deficient mesothelioma cells were shown to autonomously demethylate their ASS1 promoter to gain resistance\(^\text{[31]}\). However, more research has focused on the HIF-1α/c-Myc axis. Some cancers display a competition between the repressive HIF-1α and activating c-Myc transcription factors at the E-box of the promoter\(^\text{[15]}\). These two transcription factors seem to be regulated through a multitude of pathways that are affected by arginine deprivation.

Mammalian target of rapamycin (mTOR) activity normally upregulates HIF-1α, repressing ASS1, as shown in \textbf{Figure 2}\(^\text{[32]}\). Because mTOR is a cellular nutrient sensor, its activity is inhibited by the absence of certain amino acids, including arginine. This results in decreased HIF-1α as ADI-PEG20 inhibits mTOR in ASS1-deficient cells [Figure 2]. As HIF-1α levels decrease, the Ras/ERK pathway and phosphoinositide 3-kinase/AKT/GSK-3β kinase cascades are activated, resulting in an increase in c-Myc levels\(^\text{[15,36]}\). Specifically, ERK phosphorylates c-Myc at S62, which is stabilizing\(^\text{[33]}\). Separately, AKT inhibits GSK-3β from phosphorylating c-Myc at T58, a site that promotes degradation\(^\text{[35]}\). The two pathways thereby work
together to stabilize c-Myc as it replaces HIF-1α on the ASS1 promoter. Our understanding of how arginine starvation can be utilized with mTOR pathway modulation needs further exploration.

Another possible mechanism of resistance can result from downregulation of differentiated embryonic chondrocyte 1 (DEC1), another E-box-binding transcription factor, an upstream regulator that promotes an increase in HIF-1α and decrease in c-Myc. Silencing DEC1 increased ASS1, lending support to the hypothesis that HIF-1α/c-Myc balance is the dominant mechanism controlling ASS1 expression in many cells. However, this study used cells that lacked significant ASS1 promoter methylation in the untreated state, leaving open the possibility that an unmethylated promoter is required for expression. Performing a similar study in cells that have been shown to silence ASS1 by promoter methylation would be elucidating.

Arginine starvation can also lead to degradation of HIF-1α by way of the p300-HDAC2-Sin3A chromatin remodeling system. The histone acetyltransferase p300 normally maintains specific histone acetylations that help to stabilize HIF-1α on the ASS1 promoter. p300 dissociates upon arginine starvation, and HDAC2 deacetylates these histones, allowing the formation of a HIF-1α-proteasomal complex that leads to degradation. Although other transcription factors such as Sp4 and p53 are known to affect ASS1 transcription, there is no evidence that these factors differentially affect ASS1 expression under arginine starvation.

Upregulation of ASS1 takes time, and cells must sustain themselves in the meantime utilizing a starvation prosurvival response. For this, many ASS1-deficient cancers induce autophagy in response to ADI-PEG20.
PEG20\textsuperscript{[1,13,36]}. This is caused largely by arginine deprivation inhibiting mTORC1, which allows for increased autophagy. Autophagy, the process by which cells consume parts of themselves, enables the recycling of intracellular arginine, which is incorporated into proteins. This is a short term response. By definition, autophagy is not sustainable indefinitely as a sole source of nutrients. Cells must obtain outside resources to grow. Therefore, autophagy can serve as a sort of bridge to ASS1 upregulation and long-term resistance. However, a reliance on autophagy for any period of time presents a targetable weakness in these cells that can be exploited by combining an autophagy inhibitor with ADI-PEG20 in an attempt to kill cells before they can gain resistance. Indeed, multiple studies have shown that the autophagy inhibitor chloroquine enhances the apoptotic effect of ADI-PEG20\textsuperscript{[1,13,36]}. This combination may be more effective in an immune-competent system, as autophagy-defective T cells show enhanced anti-tumor activity\textsuperscript{[21]}.

Arginine deprivation also has major metabolic effects on arginine-auxotrophic cells which may contribute to resistance. In one study, melanoma cell lines were found to increase their reliance on both glycolysis and glutamine metabolism after becoming resistant to ADI-PEG20\textsuperscript{[3]}. Supporting this conclusion about glutamine is a paper showing that ASS1-depleted cells rely less on extracellular glutamine than ASS1-positive cells, which parallels the difference between cells that are sensitive and resistant to arginine deprivation\textsuperscript{[23]}. In addition to the increased reliance on glycolysis in melanoma cells, another study shows a shift toward oxidative phosphorylation in both melanoma and sarcoma cell lines\textsuperscript{[2]}. This study once again finds an increased dependence on glutamine metabolism in resistant cells\textsuperscript{[60]}. Multiple melanoma and breast cancer cell lines have been shown to become more resistant to glutamine deprivation as ASS1 expression increased in the absence of arginine starvation, whereas loss of ASS1 sensitizes cells to combined arginine and glutamine starvation\textsuperscript{[58]}. Many adaptive changes may be a consequence of increased c-Myc activity, which is necessary for ASS1 upregulation, rather than adaptations to help the cell survive arginine starvation\textsuperscript{[3]}. At least one study has demonstrated significant cell death when glutaminase inhibition is combined with ADI-PEG20, signifying that these cells may need glutamine in order to make more glutamate and feed the tricarboxylic acid cycle\textsuperscript{[5]}. The upregulation of c-Myc may also allow therapeutic opportunities. Active, nuclear c-Myc is greatly increased by the combination of ADI-PEG20 and docetaxel\textsuperscript{[58]}. This in turn leads to increased human equilibrative nucleoside transporter 1 expression, which imports the nucleoside analog gemcitabine, significantly enhancing its efficacy\textsuperscript{[59]}.

**Immunogenicity of ADI**

Another important aspect of the response to arginine deprivation therapy occurs only in vivo. Humans and other mammals mount a strong immune response to pure, recombinant ADI, as it is a foreign bacterial enzyme. This results in a short circulating half-life, about 4 h in mice, and severely limits its effectiveness as a drug\textsuperscript{[40]}. This is the main reason that the PEGylated version of the drug was created. The polyethylene glycol cloaks the enzyme from recognition by the immune system and greatly enhance its effectiveness in vivo\textsuperscript{[28,41]}. However, many patients still have immune responses to ADI-PEG20 over time\textsuperscript{[42,43]}. Immune reactions are much slower to occur than with pure ADI, but they can limit the time window in which ADI-PEG20 is effective. Blood arginine levels commonly show a gradual increase after roughly 8 weeks of treatment, which has been correlated to worse patient outcomes when used as a single agent\textsuperscript{[42-44]}. However, this window of effectiveness can be extended to at least 18 weeks by some combination therapies, as has been shown recently in multiple clinical trials utilizing triple drug regimens that include ADI-PEG20\textsuperscript{[45,46]}. Correlated with this was a delayed buildup of anti-ADI-PEG20 antibodies\textsuperscript{[42,44-46]}. These promising results should encourage further research to develop combination therapies that kill quickly. Additionally, the immune adaptation period can likely be harnessed for therapeutic purposes as tumors metabolically evolve in that time in vivo.
While the immune system can neutralize ADI-PEG20, the drug may also have a negative effect on the immune system by depleting arginine. Low arginine levels are known to inhibit T cell proliferation, as myeloid-derived suppressor cells do this naturally through the activity of arginase \(^1\). An arginase inhibitor therefore has potential to be effective in combination with ADI-PEG20 if anti-tumor T cells express ASS1 themselves and can make arginine. However, this may inadvertently also provide tumor cells with arginine, possibly negating the immune benefit. Arginine depletion has another detrimental effect on the anti-tumor activity of the immune system, as ASS1 upregulation causes increased programmed death-ligand 1 (PD-L1) expression, which is a negative regulator of T cells \(^4,9\). This suggests PD-1/PD-L1 immune checkpoint blockade to be used in conjunction with ADI-PEG20 \(^4,9\). There is even evidence that ADI-PEG20 can enhance infiltration of T cells into tumors in mice, giving further support to the potential of this combination \(^9\).

ASS1-deficient cells have also been found to have higher levels of cationic amino acid transporter 1 (CAT-1), which is the most important arginine importer and a potential drug target \(^5,6\). Furthermore, ASS1-deficient cells have been shown to increase import of arginine through CAT-1 in response to ADI-PEG20 treatment \(^5\). The extent of the contribution of this response to resistance was not determined, but it is likely mild and not enough to sustain growth, since extracellular arginine levels remain extremely low.

**Other mechanisms of resistance**

ASS1 re-expression and autophagy have been discussed, but there are a plethora of other ways for cells to obtain arginine, many of them unexplored as pathways for arginine deprivation resistance. Here we summarize what is known about such pathways and their relevance to ADI-PEG20 resistance. Macropinocytosis can be utilized by cancer cells to import and break down extracellular proteins for any amino acid, including arginine \(^5,2,3\). A reliance on this pathway is common in Ras-transformed cells and pancreatic cancers, but can also be used by other cancers \(^5,2,3\). It is therefore possible that macropinocytosis may be an important resistance pathway to arginine deprivation, as it has been shown to increase when mTORC1 is inhibited \(^5\). Similarly, many breast cancers can import necrotic cell debris in a process called necrocytosis \(^5\). After three days of amino acid starvation, 35%-71% of cellular protein biomass was found to originate from necrocytosed peptides, and this process also provides carbohydrates, lipids, and nucleotides \(^4,5\). Macropinocytosis and necrocytosis can also contribute significant amounts of amino acids under normal growth conditions, suggesting that these pathways could immediately provide relief from arginine starvation even without ASS1 upregulation \(^5,2,3,5\). There is also some evidence that extracellular proteins, particularly albumin, can be taken up by receptor-mediated endocytosis, although this process has not been shown to promote cell growth to the same extent as macropinocytosis \(^5,2,3,5\).

Phagocytosis is another possible pathway to resistance, albeit unlikely, as only a few cell types perform this activity. With this method, the cell would gain both cytoplasmic arginine and protein-incorporated arginine from consumed cells, exosomes, or other material, along with all other nutrients necessary for survival in the case of whole-cell phagocytosis. This phenomenon has rarely been demonstrated in nonhematopoietic cells, but some breast cancer cell lines are able to phagocytize yeast and extracellular matrix \(^5,2,7\). Some cancers can also perform a process called entosis, whereby one cell invades another \(^5\). The internal cell can then either be released or degraded by lysosomal enzymes, providing nutrients to the engulfing cell \(^5\). The end result would be almost identical to phagocytosis with regards to nutrients. It is also conceivable that slower-adapting cells are engulfed more often, which would hasten the onset of resistance in the tumor overall.

Direct sharing of arginine from other cells through gap junctions (for example, immune cells and fibroblasts in the stroma) also has not been ruled out. Heterologous gap junctions are presumably rare but have been found between some cancer and non-cancer cells \(^5,6\). However, gap junctions are generally
downregulated in cancer and therefore less likely to play a role in resistance\(^{[61]}\). Alternatively, other cells in the body may supply arginine to ASS1-deficient cancer cells indirectly. This mechanism has been shown with another amino acid, as mesenchymal cells in the microenvironment where leukemic cells grow can produce and secrete asparagine, conferring resistance to asparaginase treatment in some cases of acute lymphoblastic leukemia\(^{[62]}\). The most effective form of resistance to arginine depletion is innate. Many cancers do not downregulate ASS1 and are therefore immune to arginine deprivation therapy. Some apparently ASS1-deficient cancers may also be heterogeneous in their expression. It would take only a small number of highly expressing cells to eliminate the possibly of eradication through arginine deprivation treatment. Even if the other cells all died, ASS1-high cells would be clonally selected and grow out. This heterogeneity has not been a focus of research, but the field would benefit from its investigation.

**CURRENT CLINICAL TRIALS**

There have been many completed clinical trials involving ADI-PEG20, while others are currently active or planned. These trials are summarized in Table 1. Numerous cancer types are included across the trials, and many involve ADI-PEG20 monotherapy. However, some test ADI-PEG20 in combination with other drugs, which is likely to be more effective for many cancers that are not killed by monotherapy. There is great potential for similar combination trials in the future, as ADI-PEG20 causes many potentially targetable adaptations in ASS1-deficient cancers while having few side effects.

| NCT Number   | Conditions                                                                 | Drugs                          | Status         |
|--------------|-----------------------------------------------------------------------------|-------------------------------|----------------|
| NCT03254732  | Advanced Solid Cancers                                                     | ADI-PEG20|Pembrolizumab | Recruiting    |
| NCT02092690  | Pleural Mesothelioma Malignant Advanced | ADI-PEG20                   | Active         |
| NCT03449901  | Soft Tissue Sarcoma                                                        | ADI-PEG20|Docetaxel      | Recruiting    |
| NCT02101581  | Advanced Pancreatic Cancer                                                 | ADI-PEG20                   | Active         |
| NCT01287585  | Hepatocellular Carcinoma                                                  | ADI-PEG20                   | Completed      |
| NCT01497825  | Solid Tumors | Prostate Cancer                | ADI-PEG20                   | Completed      |
| NCT01948843  | HER2 Negative Metastatic Breast Cancer                                     | ADI-PEG20                   | Completed      |
| NCT02101993  | Hepatocellular Carcinoma                                                  | ADI-PEG20                   | Completed      |
| NCT01266018  | Small Cell Lung Cancer                                                    | ADI-PEG20                   | Terminated     |
| NCT01910012  | Acute Myeloid Leukemia                                                   | ADI-PEG20                   | Active         |
| NCT02102022  | Advanced Gastrointestinal(GI) Malignancies|Hepatocellular Carcinoma,Gastric Cancer,Colorectal Cancer | ADI-PEG20 plus modified FOLFOX6 | Recruiting |
| NCT01279967  | Malignant Pleural Mesothelioma                                           | ADI-PEG20                   | Unknown status |
| NCT02875093  | Acute Myeloid Leukemia                                                   | ADI-PEG20|Cytarabine     | Recruiting    |
| NCT01910025  | Non-Hodgkin’s Lymphoma                                                   | ADI-PEG20                   | Completed      |
| NCT02709512  | Mesothelioma                                                              | ADI-PEG20|Pemetrexed|Cisplatin     | Recruiting    |
| NCT1665183   | Cutaneous Melanoma, Uveal Melanoma, Ovarian Carcinoma or Other Advanced Solid Tumors | ADI-PEG20                   | Completed      |
| NCT01528384  | Argininosuccinate Synthetase-Deficient Cancers                           | ADI-PEG20                   | Completed      |
| NCT03498222  | Carcinoma, Non-Small-Cell Lung                                           | Atezolizumab|Pemetrexed|Carboplatin Not yet recruiting | ADI-PEG20 |
| NCT02006030  | Unresectable Hepatocellular Carcinoma                                     | ADI-PEG20                   | Completed      |
| NCT01520299  | Metastatic Melanoma | skin Cancer, Neoplasm | ADI-PEG20                   | Completed      |
| NCT00450372  | Melanoma(Skin)                                                            | ADI-PEG20                   | Completed      |
| NCT03928880  | Uveal Melanoma                                                            | ADI-PEG20|Nivolumab|Ipilimumab     | Recruiting    |
| NCT00056992  | Carcinoma, Hepatocellular                                                | ADI-PEG20                   | Completed      |
| NCT00029900  | Melanoma | Neoplasm Metastasis | ADI-PEG20                   | Completed      |

ADI-PEG20: PEGylated arginine deiminase
CONCLUSIONS
Arginine auxotrophic cancers can be targeted by enzymes that degrade arginine in the blood. However, many cancers gain resistance to the most widely used of these enzymes, ADI-PEG20, by upregulating ASS1 and converting the degradation product citrulline back into arginine. Before ASS1 levels are sufficiently increased for resistance, many cancers rely on autophagy to temporarily recycle arginine and sustain themselves. There are also other possible mechanisms by which cells could gain resistance. The most studied of these is macropinocytosis, with which cells can ingest extracellular proteins to use as amino acids sources. Additionally, some parts of a heterogeneous tumor may express higher levels of ASS1 than the rest and be resistant from the start of treatment. Cells that are sensitive to arginine deprivation respond with numerous changes in cellular metabolism and transcription factor activity, amongst other things. Many of these changes can be targeted by other drugs in combination with ADI-PEG20. Exploration of the multitude of metabolic adaptations to arginine deprivation has only just begun, and the future of therapy development is bright.

DECLARATIONS
Authors’ contributions
Wrote and edited all parts of this manuscript: Rogers LC, Van Tine BA.

Availability of data and materials
Not applicable.

Financial support and sponsorship
BAVT - reports a one year grant from Polaris, Inc. in 2014, unrelated; Basic Science Grant Funding from Pfizer, Tracon, and Merck; consulting fees from Epizyme, Lilly, CytRX, Janssen, Immune Design, Daiichi Sankyo, Bayer, Plexxicon and Adaptimmune; speaking fees from Caris, Janseen and Lilly; Travel support from Lilly; and is the overall principle investigator on (NCT03449901).

Conflicts of interest
The authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2019.

REFERENCES
1. Bean GR, Kremer JC, Prudner BC, Schenone AD, Yao JC, et al. A metabolic synthetic lethal strategy with arginine deprivation and chloroquine leads to cell death in ASS1-deficient sarcomas. Cell Death Dis 2016;7:e2406.
2. Kremer JC, Prudner BC, Lange SES, Bean GR, Schultz MB, et al. Arginine Deprivation Inhibits the Warburg Effect and Upregulates Glutamine Anaplerosis and Serine Biosynthesis in ASS1-Deficient Cancers. Cell Rep 2017;18:991-1004.
3. Long Y, Tsai WB, Wangpaichitr M, Tsukamoto T, Savaraj N, et al. Arginine Deiminase Resistance in Melanoma Cells Is Associated with Metabolic Reprogramming, Glucose Dependence, and Glutamine Addiction. Mol Cancer Ther 2013;12:2581-90.
4. Patel VB, Preedy VR, Rajendra M. L-Arginine in Clinical Nutrition. New York: Humana Press New York; 2015.
5. Dillon BJ, Prieto VG, Curley SA, Enser CM, Holtsberg FW, et al. Incidence and distribution of argininosuccinate synthetase deficiency in human cancers. Cancer 2004;100:826-33.
6. Qiu F, Huang J, Sui M. Targeting arginine metabolism pathway to treat arginine-dependent cancers. Cancer Lett 2015;364:1-7.
7. Qi X, Chen YR., Liu X, Chu CY, Shen L, et al. Arginine starvation impairs mitochondrial respiratory function in ASS1-deficient breast cancer cells. Sci Signal 2014;7:ra31.

8. Allen MD, Luong P, Hudson C, Leyton J, Delage B, et al. Prognostic and Therapeutic Impact of Argininosuccinate Synthetase 1 Control in Bladder Cancer as Monitored Longitudinally by PET Imaging. Cancer Res 2014;74:896-907.

9. Kelly MP, Jungbluth AA, Wu BW, Bomalaski J, Old LJ, et al. Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase. Br J Cancer 2012;106:324-32.

10. Miyamoto T, Lo PHY, Saichi N, Ueda K, Hirata M, et al. Argininosuccinate synthase 1 is an intrinsic Akt repressor transactivated by p53. Sci Adv 2017;3:e1603204.

11. Tissue expression of ASS1 - Summary - The Human Protein Atlas. Available from: https://v15.proteinatlas.org/ENSG00000130707-ASS1/tissue [Last accessed on 14 Aug 2019].

12. Uhlen M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, et al. Proteomics. Tissue-based map of the human proteome. Science 2015;347:1260419.

13. Delage B, Luong P, Maharaj L, O’Rian C, Syed N, et al. Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis. Cell Death Dis 2012;3:e342.

14. Huang HY, Wu WR, Yang YH, Wang JW, Fang FM, et al. ASS1 as a novel tumor suppressor gene in myxofibrosarcomas: aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance. Clin Cancer Res 2013;19:2861-72.

15. Tsai WB, Aiba I, Lee SY, Feun L, Savaraj N, et al. Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1alpha/Sp4. Mol Cancer Ther 2009;8:3223-33.

16. Szlosarek PW, Klabatsa A, Pallaska A, Sheaff M, Smith P, et al. In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion. Clin Cancer Res 2006;12:7126-31.

17. Nelson DL, Cox MM. Lehninger principles of biochemistry. New York - Basingstoke: Freeman - Macmillan; 2013.

18. Wu G, Morris SM. Arginine metabolism: nitric oxide and beyond. Biochem J 1998;336:1-17.

19. Mori M, Gotoh T. Regulation of nitric oxide production by arginine metabolic enzymes. Biochem Biophys Res Co 2000;275:715-9.

20. Rabinovich S, Adler L, Yizhak K, Sarver A, Silberman A, et al. Diversion of aspartate in ASS1-deficient tumors fosters de novo pyrimidine synthesis. Nature 2015;527:379-83.

21. Sullivan LB, Luengo A, Danai LV, Bush LN, Diehl FF, et al. Aspartate is an endogenous metabolic limitation for tumour growth. Nat Cell Biol 2018;20:785-82.

22. Garcia-Bermudez J, Baudrier L, La K, Zhu XG, Fidelin J, et al. Aspartate is a limiting metabolite for cancer cell proliferation under hypoxia and in tumours. Nat Cell Biol 2018;20:785-82.

23. Erez A, Silberman A, Goldman O, Assayag OB, Jacob A, et al. Acid-induced downregulation of ASS1 contributes to the maintenance of intracellular pH in cancer. Cancer Res 2019;79:518-33.

24. Spinelli JB, Yoon H, Ringel AE, Jeanfavre S, Clish CB, et al. Metabolic recycling of ammonia via glutamate dehydrogenase supports breast cancer biomass. Science (New York, NY) 2017;358:941-6.

25. Sciacovelli M, Gonçalves E, Johnson TI, Zecchini VR, da Costa ASH, et al. Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition. Nature 2016;537:544-7.

26. Patil M, Bhaukik J, Babykutty S, Banerjee U, Fukumura D. Arginine dependence of tumor cells: targeting a chink in cancer’s armor. Oncogene 2016;35:4957-72.

27. Oginsky EL, Gehrig RF. The arginine dihydrolase system of Streptococcus faecalis. II. Properties of arginine desimidase. J Biol Chem 1952;198:799-805.

28. Holtsberg FW, Ensror CM, Steiner MR, Bomalaski JS, Clark MA. Poly(ethylene glycol) (PEG) conjugated arginine deiminase: effects of PEG formulations on its pharmacological properties. J Control Release 2002;80:259-71.
Surface Expression to Overcome Gemcitabine Resistance in ASS1-Negative Tumors. Clin Cancer Res 2019; doi: 10.1158/1078-0432.ccr-19-0206.

40. Takaku H, Takase M, Abe SI, Hayashi H, Miyazaki K. In vivo anti-tumor activity of arginine deiminase purified from Mycoplasma argini. Int J Cancer 1992;51:244-9.

41. Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA. Pegylated Arginine Deiminase (ADI-SS PEG20,000 mw) Inhibits Human Melanomas and Hepatocellular Carcinomas in Vitro and in Vivo. Cancer Res 2002;62:5443-50.

42. Abou-Alfa GK, Qin S, Ryoo BY, Lu SN, Yen CJ, et al. Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma. Ann Oncol 2018;29:1402-8.

43. Tsai HJ, Jiang SS, Hung WC, Borthakur G, Lin SF, et al. A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients. Sci Rep 2017;7:11253.

44. Ott PA, Carvajal RD, Pandit-Taskar N, Hoffman EW, et al. Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma. Invest New Drugs 2013;31:425-34.

45. Beddowes E, Spicer J, Chan PY, Khadeir R, Corbacho JG, et al. Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers. J Thorac Oncol 2017;12:S1884.

46. Lowery MA, Yu KH, Kelsen DP, Harding JJ, Bomalaski JS, et al. A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma. Cancer 2017;123:4556-65.

47. Rodriguez PC, Quiceno DG, Ochoa AC. l-arginine availability regulates T-lymphocyte cell-cycle progression. Blood 2007;109:1568-73.

48. Szlosarek P, Khadeir R, Sheaff M, Locke M, Lau K, et al. MA 19.05 Pegylated Arginine Deiminase Potentiates PD-1/PD-L1 Immune Checkpoint Blockade in Malignant Mesothelioma. J Thorac Oncol 2017;12:S1984.

49. Brin E, Wu K, Lu HT, He Y, Dai Z, et al. PEgylated arginine deiminase can modulate tumor immune microenvironment by affecting immune checkpoint expression, decreasing regulatory T cell accumulation and inducing tumor T cell infiltration. OncoTarget 2017;8:58948-63.

50. Mirzak-Moud F, Ghazaly E, Ariza-McNaughton L, Hodby KA, Clear A, et al. Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo. Blood 2015;125:4060-8.

51. Prudner BC, Sun F, Kremer JC, Xu J, Huang C, et al. Amino Acid Uptake Measured by [18F]AFETP Increases in Response to Arginine Starvation in ASS1-Deficient Sarcomas. Theranostics 2018;8:2107-16.

52. Kamphorst JJ, Nofal M, Commisso C, Hackett SR, Lu W, et al. Human Pancreatic Cancer Tumors Are Nutrient Poor and Tumor Cells Actively Scavenge Extracellular Protein. Cancer Discov 2015;5:544-53.

53. Palms W, Park Y, Wright K, Pavlova NN, Tuveson DA, et al. The Utilization of Extracellular Proteins as Nutrients Is Suppressed by mTORC1. Cell 2015;162:259-70.

54. Kim SM, Nguyen TT, Ravi A, Kubiniok P, Finicle BT, et al. PTEN Deficiency and AMPK Activation Promote Nutrient Scavenging and Anabolism in Prostate Cancer Cells. Cancer Discov 2018;8:866-83.

55. Ghoneum M, Gollapudi S. Phagocytosis of Candida albicans by metastatic and non metastatic human breast cancer cell lines in vitro. Cancer Detect Prev 2004;28:17-26.

56. Coopman PJ, Thomas DM, Gehlsen KR, Mueller SC. Integrin alpha 3 beta 1 participates in the phagocytosis of extracellular matrix molecules by human breast cancer cells. Mol Biol Cell 1996;7:1789-804.

57. Overholtzer M, Maileux AA, Mouneimne G, Normand G, Schnitt SJ, et al. A Nonapoptotic Cell Death Process, Entosis, that Occurs by Cell-in-Cell Invasion. Cell 2007;131:966-79.

58. Ito A, Katoh F, Kataoka TR, Okada M, Tsubota N, et al. A role for heterologous gap junctions between melanoma and endothelial cells in metastasis. J Clin Invest 2000;105:1189-97.

59. Zhang ZQ, Hu Y, Wang BJ, Lin ZX, Naus CCG, et al. Effective asymmetry in gap junctional intercellular communication between populations of human normal lung fibroblasts and lung carcinoma cells. Carcinogenesis 2004;25:473-82.

60. Leithe E, Sirnes S, Omori Y, Rivedal E. Downregulation of Gap Junctions in Cancer Cells. Crit Rev Oncog 2006;12:225-56.

61. Iwamoto S, Mihara K, Downing JR, Pui CH, Campana D. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest 2007;117:1049-57.